Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Qualigen Therapeutics rises 50% after partnership with BitGo for crypto treasury

Qualigen Therapeutics announced a strategic partnership with BitGo to implement a crypto-treasury strategy and diversify corporate reserves. The company plans a multi-asset allocation of $30 million into a market-cap-weighted basket of the top ten cryptocurrencies (excluding stablecoins), secured in BitGo's regulated cold storage; BitGo's OTC desk will handle execution. » Plus sur de.investing.com
Qualigen Therapeutics appoints Kevin Chen to board

Qualigen Therapeutics has appointed Kevin Chen as an independent member of its board; Chen is chief economist and CIO at Horizon Financial and has long experience in asset management and supervisory boards. The appointment comes against a backdrop of volatile share performance (price $5.06) and a stock that InvestingPro currently rates as overvalued, with a market capitalization of around $8.6 million and ongoing profitability problems. Qualigen recently raised $4.5 million in a private placement, received a strategic investment from Faraday Future of about $30 million, and reported patent protection for its cancer drug QN-302 in 25 countries through 2040. » Plus sur de.investing.com
Qualigen meets NASDAQ requirements through private placement but remains under pressure

Qualigen Therapeutics has regained compliance with NASDAQ's equity requirements by raising $4.5 million through a private placement and has taken steps to maintain its stock market listing. The company also secured patents for its cancer drug QN-302 in 25 countries and appointed Robert B. Lim as the new chair of the audit committee. Despite these advances, the risk of delisting persists as the company continues to face challenges in meeting NASDAQ rules. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, Qualigen Therapeutics a réalisé un chiffre d'affaires de 0,00€ et un bénéfice net de −3,67M€

(EUR)	juin 2026	YoY
Chiffre d'affaires	0,00	-
Bénéfice brut	0,00	-
Bénéfice net	−3,67M	156,60%
EBITDA	−2,59M	93,51%

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	+4,66M€
Nombre d'actions	1,69M
Plus haut/bas sur 52 semaines	+7,56€ - +1,38€
Dividendes	Non
Bêta	0,28
Ratio P/E	−0,09
Ratio PEG	0,00
Ratio P/B	+3,01
Ratio P/S	0,00

Profil de l'entreprise

Qualigen Therapeutics, Inc. ist ein Biotechnologieunternehmen, das neuartige therapeutische Produkte für die Behandlung von Krebs und Infektionskrankheiten entwickelt. Es bietet FastPack, ein diagnostisches Schnelltestsystem, an. Das Unternehmen entwickelt QN-302 für die Behandlung des duktalen Adenokarzinoms der Bauchspeicheldrüse, QN-247, einen Krebsmedikamentenkandidaten mit DNA-beschichteten Goldnanopartikeln, der auf verschiedene Krebsarten abzielt, RAS-F, einen niedermolekularen RAS-Onkogen-Protein-Protein-Inhibitor, der RAS-Mutationen blockiert und die Tumorbildung hemmt, und STARS Blutreinigungssystem, ein DNA/RNA-basiertes Behandlungsgerät, das tumorproduzierte Verbindungen und Viren aus dem Blut eines Patienten entfernt. Qualigen Therapeutics, Inc. wurde 1996 gegründet und hat seinen Sitz in Carlsbad, Kalifornien.

Nom	Qualigen Therapeutics
PDG	Kevin A. Richardson II
Siège social	Carlsbad, ca États-Unis
Site web	qualigeninc.com
Secteur	Matériaux
Industrie	Produits chimiques
Introduction en bourse	23/06/2015
Employés	4